Drug_Name,STUDYID,YEAR,Country,Dataset,Patient_Count,Median_Age,Female_Percentage,Male_Percentage,Median_BMI,Smoking_History_Yes_Percentage,Total_ADL_Independence_Percentage,LHRH_Use_Percentage,Tumor_Stage_T1_Percentage,Tumor_Stage_T2_Percentage,Tumor_Stage_T3_Percentage,Tumor_Stage_T4_Percentage,Nodal_Stage_N0_Percentage,Nodal_Stage_N1_Percentage,Nodal_Stage_N2_Percentage,Nodal_Stage_N3_Percentage,Stage_I_Percentage,Stage_II_Percentage,Stage_III_Percentage,Diabetes_Mellitus_Percentage,Congestive_Heart_Failure_Percentage,Stroke_Percentage,Atrial_Fibrillation_Percentage,Myocardial_Infarction_Percentage,Neoadjuvant_Chemotherapy_Received_Percentage,Adjuvant_Chemotherapy_Received_Percentage,Postoperative_RT_Received_Percentage,Common_Neoadjuvant_Regimen_1,Common_Neoadjuvant_Regimen_2,Common_Adjuvant_Regimen_1,Common_Adjuvant_Regimen_2,Tamoxifen_Percentage,Letrozole_Percentage,Anastrozole_Percentage,Antidiarrheal_Agent_Probiotics_Percentage,Antiemetic_Agent_Percentage,Painkiller_Antipyretic_Percentage,Beds_Less_Than_200_Percentage,Beds_200_To_499_Percentage,Beds_Greater_Or_Equal_To_500_Percentage,Designated_Cancer_Hospital_Percentage,Months_Between_Surgery_And_Index_Date
Xgeva (Denosumab),XgevaStudy001,2021,USA,MDV,350,68,45,55,27.5,32,85,25,15,30,40,15,55,25,15,5,20,35,30,18,8,5,12,7,10,20,35,Docetaxel + Cyclophosphamide,AC (Adriamycin + Cyclophosphamide),AC-T (Adriamycin + Cyclophosphamide followed by Taxol),TC (Docetaxel + Cyclophosphamide),15,25,30,22,40,55,15,45,40,60,2
Xgeva (Denosumab),XgevaStudy002,2022,Canada,Claim Database,420,72,52,48,28.1,28,78,30,12,28,42,18,50,28,17,5,18,32,35,20,10,6,14,8,12,22,38,"FEC (5-Fluorouracil, Epirubicin, Cyclophosphamide)",Taxol + Trastuzumab,Taxol + Carboplatin,"CMF (Cyclophosphamide, Methotrexate, 5-Fluorouracil)",18,28,32,25,45,60,10,50,40,65,3
Xgeva (Denosumab),XgevaStudy003,2023,UK,MDV,280,65,48,52,26.9,35,90,22,18,32,38,12,60,22,13,5,22,38,25,15,7,4,10,6,8,18,32,"EC (Epirubicin, Cyclophosphamide)",Docetaxel + Pertuzumab + Trastuzumab,"FEC-D (5-Fluorouracil, Epirubicin, Cyclophosphamide followed by Docetaxel)",AC (Adriamycin + Cyclophosphamide),12,22,28,20,35,50,20,40,40,55,2.5
Xgeva (Denosumab),XgevaStudy004,2023,Australia,Claim Database,480,70,55,45,29.0,30,80,28,14,29,41,16,52,26,16,6,19,33,33,22,9,5,13,7,11,21,37,AC-TH (Adriamycin + Cyclophosphamide followed by Paclitaxel + Trastuzumab),"TCHP (Docetaxel, Carboplatin, Trastuzumab, Pertuzumab)",TC (Docetaxel + Cyclophosphamide),AC-T (Adriamycin + Cyclophosphamide followed by Taxol),16,26,31,23,42,58,12,48,40,62,2.8
